Picobella’s core retroviral mutagenesis technology performs functional genomics in vivo. By means of this platform, all genes in the genome are simultaneously tested in live mice and sheep for the ability to cause tumorigenesis. These functionally validated targets are identified using a process combining provirus insertion and chemical mutagenesis. Picobella has adapted its technology to an industrial scale and is screening over 8000 mice and sheep, the largest private or public effort to date. Both oncogenes (i.e., genes that cause cancer when mutated in somatic cells) and tumor suppressor genes (i.e., genes that cause cancer when deleted in somatic cells) are specifically identified in the comprehensive genetic screen. These gene targets are then further analyzed for relevance to cancer in humans.